QUIDS self-report scale

Software / App

A self-report measure used in the psilocybin vs. Lexapro study as a primary outcome, which showed no significant difference between the two treatments at six weeks, leading to the study being "undersold" as negative.

Mentioned in 1 video

Videos Mentioning QUIDS self-report scale

182 - Psychedelics & Recreational Drugs

182 - Psychedelics & Recreational Drugs

Peter Attia MD

A self-report measure used in the psilocybin vs. Lexapro study as a primary outcome, which showed no significant difference between the two treatments at six weeks, leading to the study being "undersold" as negative.